rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VSTM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Verastem Stock In Focus After Earnings Update And New Financing Plans
      Nov 13Yahoo FinanceVSTM
      Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
      Nov 11Yahoo FinanceVSTM
      Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
      Nov 10Yahoo FinanceVSTM
      Verastem at Guggenheim healthcare conference: push for G12D lead
      Nov 9Investing.comVSTM
      What Verastem (VSTM) Said on Its Q3 Earnings Call
      Nov 7Yahoo FinanceVSTM
      Verastem (VSTM) Wins FDA Priority Review, Is The Stock Cheap Or Priced For More?
      Nov 6Yahoo FinanceVSTM
      Verastem, Inc. Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceVSTM
      H.C. Wainwright raises Verastem stock price target to $20 on drug progress
      Nov 6Investing.comVSTM
      Verastem Inc (VSTM) Q3 2026 Earnings Call Highlights: Avmapki Revenue Surges 114% as VS-7375 ...
      Nov 6Yahoo FinanceVSTM
      Verastem CEO Dan Paterson sells $12,470 in company stock
      Nov 6Investing.comVSTM
      Verastem Oncology Q3 2026 Earnings Call Transcript
      Nov 5BenzingaVSTM
      Verastem earnings missed by $0.25, revenue fell short of estimates
      Nov 5Investing.comVSTM
      Verastem: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceVSTM
      Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
      Nov 5Yahoo FinanceVSTM
      Verastem Oncology to Participate in Upcoming November Investor Conferences
      Nov 2Yahoo FinanceVSTM
      Does Verastem (VSTM) Still Trade Near Fair Value On Sales?
      Oct 30Yahoo FinanceVSTM
      Novocure partners with Verastem on pancreatic cancer trial
      Oct 28Investing.comNVCRVSTM
      What Verastem (VSTM)'s Trial Update Means For Shareholders
      Oct 24Yahoo FinanceVSTM
      Wainwright reiterates Verastem stock rating on China trial data
      Oct 16Investing.comVSTM
      Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap?
      Oct 16Yahoo FinanceVSTM
      VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
      Oct 15Yahoo FinanceVSTM
      Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says
      Oct 15Yahoo FinanceVSTM
      Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
      Oct 15Yahoo FinanceVSTM
      Mizuho raises Verastem stock price target on strong trial data
      Oct 15Investing.comVSTM
      Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating
      Oct 15Yahoo FinanceVSTM
      RBC Raises Price Target on Verastem to $19 From $14, Keeps Outperform, Speculative Risk
      Oct 15Yahoo FinanceVSTM
      Verastem: A Real Pancreatic Cancer Drug, Arriving Second (NASDAQ:VSTM)
      Oct 15Seeking AlphaRVMDVSTM
      RBC Capital raises Verastem stock price target to $19 on G12D data
      Oct 15Investing.comVSTM
      Verastem Oncology Announces CEO Transition to Michael Bailey

      Detailed price information for Verastem Inc (VSTM-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailVSTM
      Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers - Slideshow (NASDAQ:VSTM) 2026-10-14
      Oct 14Seeking AlphaVSTM
      Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
      Oct 14Yahoo FinanceVSTM
      Verastem cancer drug shows early promise in small study

      Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

      Oct 14Yahoo FinanceVSTM
      Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers - Veraste

      Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.

      Oct 14BenzingaVSTM
      Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday - Bending Spoons (NASD

      U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.

      Oct 14BenzingaLQDAVSTM
      Verastem Gets a New CEO and $250 Million to Advance Its Cancer Pipeline

      Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

      Oct 14Barron'sVSTM
      Why is Verastem stock surging today?
      Oct 14Investing.comVSTM
      Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know
      Oct 14Yahoo FinanceVSTM
      Verastem names Michael Bailey as CEO effective January 2027
      Oct 14Investing.comVSTM
      Verastem Cancer Drug Shows Responses in Pancreatic, Lung, and Colorectal Cancers
      Oct 14Yahoo FinanceVSTM
      Verastem Oncology Names Michael Bailey CEO; Prices $250 Million Offering -- Shares Rise Pre-Bell
      Oct 14Yahoo FinanceVSTM
      Verastem drug shows strong anti-tumor activity across advanced KRAS G12D-mutant cancers (VSTM:NASDAQ)

      Verastem (VSTM) shares jump on VS-7375 KRAS G12D data: up to 50% ORR in 2L pancreatic cancer at 900 mg.

      Oct 14Seeking AlphaVSTM
      Verastem Oncology prices $250 million stock offering
      Oct 14Investing.comVSTM
      Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
      Oct 14Yahoo FinanceVSTM
      Verastem Oncology Q2 2026 Earnings Call Transcript - Verastem (NASDAQ:VSTM)

      Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and

      Oct 12BenzingaVSTM
      Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

      The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Oct 12Yahoo FinanceVSTM
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

      Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailRAREVSTM
      B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating
      Oct 7Yahoo FinanceVSTM
      Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM)

      Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor. Learn why VSTM stock is a buy.

      Oct 6Seeking AlphaVSTM
      Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 5Yahoo FinanceVSTM
      Verastem stock maintained at Buy by BTIG ahead of data readout
      Oct 5Investing.comVSTM

      This is the newest page. Registered accounts read further back.